Clinical Trial Update: CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) [Phase 1, Phase 2]

View source ↗

Summary

A CD318-targeted CAR-T cell therapy (ResCPa) is being studied in pancreatic cancer patients in Phase 1 and Phase 2, and the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CD318-targeted CAR-T cell therapy (CD318-targeted CAR-T cells)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING